Taku Yamashita, MD
Articles
UFT Plus Carboplatin for Head and Neck Cancer
Masato Fujii, MD;Yoshihiro Ohno, MD;Yutaka Tokumaru, MD;Yorihisa Imanishi, MD;Minoru Kanke, MD;Toshiki Tomita, MD;Taku Yamashita, MD
October 1st 2000Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer.
Latest Updated Articles
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: July 31st 2012 | Updated: December 24th 2024
NSCLC Patient Develops Fever and Rash Following Treatment for Brain Metastases
Published: August 26th 2011 | Updated: December 24th 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
